
As US health authorities consider whether to allow AstraZeneca to resume the clinical trial of its coronavirus vaccine, crucial questions remain about neurological illnesses suffered by study participants who received injections of the experimental vaccine.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push